applied a CytoLytic Virus Activation (CLVA) therapy in patients with recurrent NPC. 10 CLVA treatment combines the cytostatic drug gemcitabine (GCb) with histone deacetylase inhibitor (HDACi) valproic acid (VPA) to trigger reactivation of latent EBV into the lytic cycle. [10] [11] [12] The induced expression of early viral kinases TK (BXLF1) and PK (BGLF4) sensitizes tumor cells to the antiviral compound ganciclovir (GCV) providing increased cytotoxicity. 11 EBV immediate early (IE) gene products Zebra or Zta, and Rta play a central role in triggering the latency-to-lytic switch and block G1/S transition, thus limiting cell growth. 13 Moreover, tumor cells switched to the viral lytic phase become targets for abundant cytotoxic T-cell directed toward lytic gene products. 6 Therefore, in recent years an increasing effort is made in finding novel compounds and drug combinations that can efficiently trigger EBV lytic reactivation. GCb is an effective single agent for treatment of NPC 14, 15 and capable of reactivating EBV in epithelial cells.
This activity is enhanced by the chromatin remodeling activity of histon deacetylase inhibitors (HDACi-s) and DNA demethylating agents. 12, 16, 17 Initial studies on CLVA were pioneered in treating EBV-positive lymphomas in transplant recipients. 18, 19 Recently, CLVA therapy was administered to end-stage NPC patients showing promising results. 10, 20 To investigate biological effects of CLVA therapy and the in vivo kinetics which is phosphorylated by early lytic-phase kinases (TK and PK) and used for in vivo imaging and ex vivo bio-distribution. 21 [
I]-FIAU-PET/
CT is approved for clinical use in musculoskeletal bacterial infections 22 and might be translated for monitoring CLVA treatment in NPC patients.
| MATERIALS AND METHODS

| Establishment of NPC mouse model and CLVA treatment
The EBV-positive carcinoma cell line C666.1 was cultured as described before. 10 Balb/c nude mice (Harlan, Zeist, the Netherlands) were injected sub-cutaneously (s.c.) with three million C666.1 cells in matrigel (BD Biosciences, Erembodegem, Belgium) in left and right flank. Tumor volume (TV) was measured twice weekly and blood sampling (50-100 μL) from the tail vein was done weekly. Animal experiments were conducted in accordance with the Dutch law and the protocol was approved by the VUMC committee on animal experimentation. Drugs were administered when tumor size reached 100-300 mm 2 , or 300-500 mm 2 for Positron Emission Tomography (PET) scan experiments. Animals were randomized before treatment. Drug doses were based on prior in vivo studies 10, 11, 23 and the administration schedule mimicked a single cycle of human CLVA therapy. 10, 20 CLVA treatment consisted of daily 300 mg/kg VPA (SigmaAldrich, Zwijndrecht, the Netherlands) in fresh drinking water and 120 mg/kg GCb (Fresenius Kabi Oncology Plc., Bordon, UK) administered i.p., followed after 4 days by daily i.p. treatment with 100 mg/kg GCV (Sigma-Aldrich) (Fig. 1A) . All groups (n = 5 per group) were treated for 15 days and subsequently animals were sacrificed and tumors harvested.
Half of the tumor was snap frozen in liquid nitrogen and half was formalin fixed, paraffin-embedded (FFPE) for histopathology, and immunohistochemistry examinations.
For PET-scan and tissue bio-distribution analyses, two groups of mice (n = 4) were treated with one dose of GCb and daily VPA. After 6 and 9 days, 1 group of animals was used for PET analysis (Fig. 1B) . In parallel one group received GCb and VPA but no PET tracer and were sacrificed after 6 days of treatment and tumor tissue was harvested for molecular and histological analyses.
2.2 | EBV DNA load in whole blood before and during treatment
Every week starting from day 6 after tumor inoculation, 50 μL whole blood (WB) was collected mixed well with 450 μL NucliSens lysisbuffer (ioMérieux, Marcy-l'Étoile, France). DNA was isolated and viral DNA load was measured as described before. 10, 24 All samples were spiked with 1000
copies of EBV plasmid to analyze potential PCR inhibition. Cruz, Dallas, TX) antibodies was performed as described earlier. After 24 h, a 1 h the emission scan was started. PET-scan data were corrected for scatter, random noise, attenuation, decay, and dead time using iterative 3D ordinary Poisson ordered-subsets expectation maximization (OSEM).
| Ex vivo tissue distribution
Immediately after PET, blood was obtained by heart puncture of anesthetized animals. Urine, tumors, thyroid, liver, spleen, kidney, skeletal muscle, stomach, ileum, bladder, brain, and lymph nodes were harvested from four mice. Tissues were weighed and the amount of radioactivity determined using a gamma counter (LKB 3.2 | EBV DNA load in mouse whole blood reflects tumor volume Viral DNA levels in WB monitored in parallel to the treatment response (Fig. 2B) gradually increased with tumor volume until the start of treatment (day 13). The levels continued to rise in untreated, as well as in VPA-only and GCV-only treated groups reaching a plateau of 1 × 10 5 copies/mL, while in GCb-only, GCb/VPA, and complete CLVA treated groups, a steep decrease of viral load was observed at 5 days from treatment initiation (Fig. 2B ), which remained negative in GCb/VPA and complete CLVA treated groups during follow-up. In the GCb-only treated group three animals showed a rise in EBV DNA load on day 30 (3 × 10 2 copies/mL blood), suggesting tumor regrowth. No such increase was observed in the complete CLVA treated animals.
| The kinetics of lytic virus induction in vitro
EBV reactivation in C666.1 cells treated with GCb/VPA (1-8 days) was analyzed to determine optimal timing for administration of radiolabeled FIAU. EBV-mRNA profiling revealed significant upregulation of all lytic targets starting after 3 days of treatment (Fig. 3A) . Lytic induction was also assessed based on appearance of IE-Zebra and early lytic PK proteins by immunoblot analysis of parallel samples (Fig. 3B ).
Zebra expression increased after 24 h of GCb/VPA treatment and reached a plateau level after 3 days, decreasing thereafter. PK appeared after 3 days of treatment and expression increased in time to stable levels throughout.
| Lytic transcripts detected after 6 and 9 days GCb and VPA treatment in vivo
Based on the in vitro mRNA expression kinetics in vivo EBV-RNA profiling was performed in extracts of frozen tumors from GCb/VPA treated animals harvested at 6 and 9 days following treatment and from untreated mice 30 days after tumor inoculation. In the untreated control group only negative or very low base-levels of lytic transcripts were detectable. In 6-days, CLVA treated mice transcripts of Zebra, Rta, PK, TK, and VCA-p18 appeared to be present in high numbers indicating viral lytic induction due to GCb/ VPA treatment (Fig. 4) . The levels decreased in tumors of day 9 treated mice, except for the late VCA-p18 transcripts. Latent-phase specific EBV RNA transcripts were detected in all tumor tissues, and the expression pattern corresponded to the NPC-specific EBV latency type-II (data not shown).
| CLVA treatment results in strong reduction of EBER-positive tumor cells
Tumor tissues collected after treatment were examined for the presence of EBV-positive cells using the EBER-RNA in situ hybridization assay (EBER-RISH) and tissue architecture was inspected by routine HE staining (Fig. 5 ). In the untreated group of animals, large fields of tightly packed vital tumor cells were surrounded by tumor stroma and as indicated by strong EBERpositive staining (Fig. 5A,D) . This pattern was similar in tumors from animals treated with VPA and GCV-only ( Supplementary   Fig. S1A-C) . In GCb-only treated animals, tumor tissue architecture 
| Lytic EBV reactivation in tumors of mice treated with GCb and VPA
To investigate EBV lytic induction in tumor tissues, we performed IHC staining for IE lytic protein Zebra for all animals treated with GCb/VPA combination, after 6, 9, and 15 days and non-treated controls.
Histopathological analyses revealed most abundant Zebra expression (Fig. 3) , we argued that FIAU should be administered, after 4-5 days following the first administration of GCb/VPA, in order to achieve optimal PK/TK mediated conversion and cellular accumulation. Accumulation of (Fig. 6A) . previous in vitro studies. [10] [11] [12] The abundant infiltration of active mouse macrophages in these tissues supports a role of phagocytic cells in apoptotic tumor cell clearance (Fig. 5K-M) . In patients, the viral neo-antigens after EBV reactivation are considered to be crucial for triggering EBV-specific activation of T-cell mediated immune response. 6 This aspect however cannot be assessed in this nudemouse model. One of the highly immunogenic EBV products, IE protein Zebra was detected in tumor tissues of 6 days treated mice, indicating a single dosage of CLVA induced reactivation of virus in NPC tumor cells (Fig. 5G-J) . The fact that we detected sporadic single Zebra-positive cells in untreated tumors suggests a spontaneous EBV-reactivation. This is in agreement with in vitro findings, 17 indicating that a subset of cells can be induced for strong Zebra expression by a single-dose treatment whereas multiple cells are weakly induced, which may remain undetectable by immunohistochemistry in vivo. Apparently the process is highly dynamic, since only 3 days later (9 days treated mice), the expression of Zebra dropped significantly which was in line with the lytic mRNA profiles showing a peak of EBV-reactivation after 6 days of treatment followed by a decreases in time. GCV alone is not effective for treating EBV-positive tumors, 11, 16 since tumor cells do not express viral kinases to convert GCV into its cytotoxic tri-phosphate form. In the NPC mouse model of Sides et al, 31 a small reduction in TV of GCV-only treated mice was found, due to mild pro-apoptotic properties of this compound. We did not observe any inhibition of tumor growth by GCV-only treatment, similar to findings in a B-cell lymphoma mouse model. 12 
